Skip to content

Current Debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.31B-35.1%
Gilead Sciences logo
Gilead SciencesGILD
$1.31B-53.2%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$221K-56.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s current debt?
Artiva Biotherapeutics, Inc. (ARTV) reported current debt of $11K in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s current debt changed year-over-year?
Artiva Biotherapeutics, Inc.'s current debt decreased by 91.3% year-over-year, from $126K to $11K.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.